Open Orphan (LSE:ORPH) advanced 3% to 23.7p on Monday morning after revealing a contract renewal expected to deliver “significant revenue” over the next 12 months. The specialist pharma services...

Open Orphan (LSE:ORPH) advanced 3% to 23.7p on Monday morning after revealing a contract renewal expected to deliver “significant revenue” over the next 12 months. The specialist pharma services...
Open Orphan (LSE:ORPH) We may have entered a new year, but momentum at Open Orphan continues to build at pace. On Wednesday, the rapidly-growing pharma services firm and AIM darling announced that...
The first volunteer has been dosed with a COVID-19 vaccine as part of hVIVO’s phase 1 clinical trial of COVI-VAC. Following on from its announcement in July last year, the CRO, part of Open Orphan...
Open Orphan PLC (LSE: ORPH) has recently extended a contract with a top-three global pharma company. Its Venn Life Services subsidiary, operating out of Breda, Netherlands, will provide chemistry,...
Open Orphan (LSE: ORPH) subsidiary Venn Life Sciences has extended a consulting contract with a global pharma firm to support two vaccine development programmes. Venn’s Breda office in the...
Human challenge study pioneer and AIM darling Open Orphan (LSE:ORPH) is set for a record-breaking 2021. The joint London and Dublin-listed pharma services firm is now profitable for the first...
Open Orphan (LSE:ORPH) has bagged its second major contract with a top-three global pharmaceutical company in as many months. On Monday, the contract research organization services company revealed...
Huge biotech potential at XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT) Biotechs are among the most profitable, highest-margin businesses on earth. Why? Exclusivity and first-mover advantage....
Have you ever wondered how the Big Pharma companies got so big? Just look at some of their market caps. Roche (SWX:RO) is worth $290 billion. Novartis (SWX:NOVN) is worth $220 billion....